Corbus Pharmaceuticals Holdings, Inc. (CRBP) Director David P. Hochman Buys 10,000 Shares of Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director David P. Hochman bought 10,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was bought at an average price of $7.08 per share, with a total value of $70,800.00. Following the transaction, the director now owns 459,500 shares in the company, valued at $3,253,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) opened at $6.85 on Tuesday. Corbus Pharmaceuticals Holdings, Inc. has a 12-month low of $5.30 and a 12-month high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The company had revenue of $0.80 million during the quarter. equities analysts anticipate that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Corbus Pharmaceuticals Holdings, Inc. (CRBP) Director David P. Hochman Buys 10,000 Shares of Stock” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.thestockobserver.com/2017/11/14/corbus-pharmaceuticals-holdings-inc-crbp-director-david-p-hochman-buys-10000-shares-of-stock.html.

Several institutional investors and hedge funds have recently made changes to their positions in CRBP. State Board of Administration of Florida Retirement System acquired a new position in shares of Corbus Pharmaceuticals Holdings during the 3rd quarter worth $108,000. Voya Investment Management LLC acquired a new position in shares of Corbus Pharmaceuticals Holdings during the 2nd quarter worth $125,000. Capital Fund Management S.A. acquired a new position in shares of Corbus Pharmaceuticals Holdings during the 2nd quarter worth $130,000. Credit Suisse AG acquired a new position in shares of Corbus Pharmaceuticals Holdings during the 1st quarter worth $157,000. Finally, Nationwide Fund Advisors acquired a new position in shares of Corbus Pharmaceuticals Holdings during the 2nd quarter worth $158,000. Institutional investors own 29.20% of the company’s stock.

A number of equities research analysts have issued reports on CRBP shares. Cantor Fitzgerald set a $24.00 target price on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Noble Financial reiterated a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, August 9th. ValuEngine downgraded shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $20.75.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply